Market Overview

No Fundamental Reason For Boston Scientific Shares' Underperformance, RBC Upgrades Stock


Shares of Boston Scientific Corporation (NYSE: BSX) have lost more than 6 percent over the past six months, which has at least one analyst suggesting investors take advantage of the underperformance.

The Analyst

RBC Capital Markets' Glenn Novarro upgraded Boston Scientific's stock from Outperform to Top Pick with an unchanged $31 price target.

The Thesis

There is no "fundamental foundation" to explain why Boston Scientific's stock has underperformed the broader market, Novarro said in a note. As such, the stock now boasts the best risk to reward profile among the analyst's entire large-cap coverage. The stock could see a catalyst as soon as Feb. 1 when the company releases its fourth quarter earnings report which will likely eliminate investor concerns around 2018 guidance.

Specifically, the company's management team is likely to reaffirm a 5 to 7 percent revenue growth forecast for 2018, the analyst said. This figure is consistent with what was offered during the 2017 Investor Day event in June. However, recent product approvals in Rhythm Management and MedSurg could outperform and see a growth rate of 6 to 7 percent in 2018. This is especially encouraging when factoring in management's 5 to 6 percent initial guide.

Meanwhile, Wall Street's consensus EPS estimate of 2018 of $1.38 appears low and implies only a 4 percent year-over-year growth over, the analyst said. Also, foreign exchange rates are likely to help increase the company's revenue and EPS in the first half of 2018.

"BSX has the second highest organic revenue growth forecast in our large-cap coverage, and yet its shares trade in-line or at a discount to shares of companies with lower organic revenue and EPS growth," Novarro concluded.

Price Action

Shares of Boston Scientific gained 2.5 percent Friday to $25.97.

Related Links:

JPMorgan: Buy The Boston Scientific Dip

Stephens' Analysts Present Their Best Ideas For 2018

Latest Ratings for BSX

Dec 2018Credit SuisseInitiates Coverage OnOutperform
Nov 2018UBSInitiates Coverage OnBuy
Oct 2018ArgusMaintainsBuyBuy

View More Analyst Ratings for BSX
View the Latest Analyst Ratings

Posted-In: Glenn Novarro MedSurg RBC Capital Markets Rhythm ManagementAnalyst Color Upgrades Analyst Ratings


Related Articles (BSX)

View Comments and Join the Discussion!

Latest Ratings

VREXNorthland SecuritiesInitiates Coverage On42.0
EAMorgan StanleyMaintains88.0
ELMorgan StanleyMaintains178.0
SPLKMorgan StanleyMaintains140.0
View the Latest Analytics Ratings
Don't Miss Out!
Join Our Newsletter
Subscribe to:
Trader Essentials
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Thank You
for registering for Benzinga’s newsletters and alerts.
• The Daily Analysts Ratings email will be received daily between 7am and 10am.
• The Market in 5 Minutes email will be received daily between 7am and 8am.
• The Fintech Focus email will be received every Friday between 2pm and 5pm.

Box Office Preview: 'Insidious' Unlikely To Crack Top Of The Box Office

Baird Goes Neutral On Johnson Controls: 'Our Prior Thesis Has Failed To Materialize'